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Abstract
Background: Positron emission tomography (PET) with the liver-specific galactose tracer
2-[18F]fluoro-2-deoxy-D-galactose (18F-FDGal) may improve diagnosis of hepatocellular carcinoma (HCC). The aim of
this study was to test which of three different 18F-FDGal PET protocols gives the highest tumour-to-background
(T/B) ratio on PET images and thus better detection of HCC tumours.
Methods: Ten patients with a total of 15 hepatic HCC tumours were enrolled prior to treatment. An experienced
radiologist defined volumes of interest (VOIs) encircling HCC tumours on contrast-enhanced CT (ce-CT) images.
Three PET/CT protocols were conducted following an intravenous 18F-FDGal injection: (i) a 20-min dynamic PET/CT
of the liver (to generate a 3D metabolic image), (ii) a traditional static whole-body PET/CT after 1 h, and (iii) a late
static whole-body PET/CT after 2 or 3 h. PET images from each PET/CT protocol were fused with ce-CT images, and
the average standardized uptake values (SUV) in tumour and background liver tissue were used to calculate (T/B)
ratios. Furthermore, Tpeak/B ratios were calculated using the five hottest voxels in all hot tumours. The ratios for the
three different PET protocols were compared.
Results: For the individual tumours, there was no significant difference in the T/B ratio between the three PET
protocols. The metabolic image yielded higher Tpeak/B ratios than the two static images, but it was easier to identify
tumours on the static images. One extrahepatic metastasis was detected.
Conclusions: Neither metabolic images nor static whole-body images acquired 2 or 3 h after 18F-FDGal injection
offered an advantage to traditional whole-body PET/CT images acquired after 1 h for detection of HCC.
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Background
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer and the second most frequent cause
of cancer-related death worldwide [1]. In more than
90 % of the cases, the development of HCC is associated
with a known risk factor such as liver cirrhosis or
chronic viral hepatitis [2]. The European Association for
the Study of the Liver (EASL) recommends diagnosis of
HCC be based on multiphase contrast-enhanced (ce-)
CT and/or MRI with specific radiological hallmarks (ar-
terial hypervascularity and venous/delayed washout).
Two imaging protocols are recommended for small
(<1 cm) tumours, and biopsy is recommended in non-
cirrhotic cases and when radiology is inconclusive [3].
The challenge is to identify small tumours, which are
potentially curable [3].
During malignant transformation, a tumour might
change metabolism before morphological changes be-
come visible on CT or MRI. For that reason, positron
emission tomography with integrated computed tomog-
raphy (PET/CT) is widely used for diagnosis and staging
of a broad range of cancer types. The glucose analogue
2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) is the most
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commonly used PET tracer for detecting malignancies,
but for HCC, the diagnostic sensitivity of 18F-FDG PET/
CT is only 50–70 % [4–7].
Galactose is almost exclusively metabolized in hepato-
cytes, and a proof-of-concept PET/CT study of 39 patients
with the galactose analogue 2-[18F]fluoro-2-deoxy-D-galact-
ose (18F-FDGal) showed promising results for detection of
HCC [8]. For hepatic lesions, the sensitivity of 18F-FDGal
PET/CT was similar to that of ce-CT, and 18F-FDGal PET/
CT detected previously unknown extrahepatic disease in
eight patients [8]. The tumour-to-background (T/B) ratio
was however relatively low for hepatic lesions, and we
hypothetized that the ratio between tumour and back-
ground could be enhanced by delayed PET/CT acquisition
2 or 3 h after tracer administration as it has been suggested
for 18F-FDG [9]. In addition, the so-called metabolic images
of the hepatic clearance of 18F-FDGal created using a dy-
namic 18F-FDGal PET/CT protocol can be used to quantify
regional hepatic metabolic function in vivo [10, 11]. Meta-
bolic images might have an advantage to static imaging as
it was shown for 18F-FDG PET of cholangiocarcinoma [12]
because they depict differences in metabolic capacity, i.e.
enzymatic activity.
The aim of the present study was to determine whether a
metabolic image (generated from a 20-min dynamic PET/
CT) or a late static PET/CT 2 or 3 h after tracer injection
might provide better tumour detection than a traditional
static PET/CT after 1 h.
Methods
Ten patients with HCC diagnosed according to the
EASL-EORTC guidelines [3] were enrolled in the study.
All tumours were visible on multiphase ce-CT, and the
diagnosis was confirmed by histology in seven patients.
The ce-CT was performed on average 22 days before the
present study (range, 4–46 days) and according to guide-
lines [3]. Patients were enrolled prior to treatment.
Three patients had previously been treated for HCC;
two had been treated with transarterial chemoemboliza-
tion and one had undergone hepatic resection, but all
three subjects were presenting with relapse now and en-
rolled before treatment of their recurrent tumours.
The study was approved by The Central Denmark Region
Committees on Health Research Ethics and conducted in
accordance with the Helsinki Declaration. Informed con-
sent was obtained from all individual participants included
in the study.
ce-CT protocol
The CT images of the liver were obtained with a 64-
detector CT scanner (Brilliance™, Philips Healthcare, Best,
Netherlands). The following CT parameters were used:
64 × 0.625 mm collimation, section thickness 2.0 mm, in-
crement of 1.0, 120–140 kVp, and 200–250 mAs. A bolus
of minimum 85 mL to a maximum of 153 mL (1.7 mL/kg
total body weight) non-ionic contrast agent (Visipaque™,
320 mg I/mL; GE Healthcare, Oslo, Norway) was adminis-
tered to all patients at a rate of 4.0 mL/s. A bolus-tracking
technique was used to compensate for differences in car-
diac output. The trigger region of interest (ROI) was placed
in the thoracic aorta, and when it exceeded 150 HU, the
liver was scanned with a delay of 15 s (arterial phase) and
50 s (portal venous phase).
18F-FDGal PET/CT protocol
All subjects were studied in supine position using the
same PET/CT camera, a 64-slice Siemens Biograph True-
point PET/CT camera (Siemens AG, Erlangen, Germany).
Patients fasted for at least 6 h before the study but were
encouraged to drink water. Nine subjects had an Artflon
catheter (Artflon, Ohmeda, Swindon, UK) placed percu-
taneously in a radial artery for blood sampling during the
dynamic PET protocol.
Dynamic PET/CT
Before the dynamic PET/CT, a topogram was performed
for optimal positioning of the liver within the 216-mm
transaxial field of view of the PET camera followed by a
low-dose CT scan (50 effective mAs with CARE Dose4D,
120 kV, pitch 0.8, slice thickness 5 mm) for attenuation
correction of PET data. At time = 0, the dynamic PET
scan was started (list mode) and a bolus of 100 MBq
18F-FDGal in 10 mL saline was administered intraven-
ously in a cubital vein over the time course of 15–20 s.
18F-FDGal was produced in our own radiochemistry la-
boratory (radiochemical purity ≥97 %) [13]. Arterial
blood samples (0.5 mL) were collected manually at times
18 × 5 s, 1 × 10 s, 4 × 20 s, 2 × 30 s, 2 × 1.5 min, and 6 ×
2 min, total 19 min (the last blood sample at the midpoint
of the last reconstructed time frame), for determination of
blood concentrations of 18F-FDGal (kBq/mL blood) using
a well counter (Packard Instruments, Meriden, CT, USA)
and corrected for radioactivity decay back to time = 0.
Time course of the blood concentration of 18F-FDGal in
the patient without Artflon (patient #1) was obtained from
a volume of interest in the posterior part of the aorta
(aorta-VOI) [14].
Static PET/CT
One hour after tracer administration, a standard whole-
body PET/CT was performed from the mid-thigh to
the cranial vertex with an acquisition time of 3 min/bed
position (5–6 bed positions) and low-dose CT scan (50
effective mAs with CARE Dose4D, 120 kV, pitch 0.8,
slice thickness 5 mm) for attenuation correction of PET
data. Two (patients #1–4) or three (patients #5–10)
hours after tracer administration, the static PET/CT
protocol was repeated with an acquisition time of
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4 min per bed position for the protocol after 2 h and
5 min per bed position for the protocol after 3 h. The
acquisition time after 2 and 3 h was increased to ac-
count for radioactive decay of the injected 18F-FDGal.
Reconstruction of data
The dynamic PET data were reconstructed with resolution
modelling, 336 × 336 matrix, voxel size 2 × 2 × 2 mm3, 4 it-
erations, 21 subsets, separate prompts/randoms, and a 2.0-
mm FWHM Gaussian post reconstruction filter. Measure-
ments were corrected for radioactivity decay back to t = 0.
Time-frame structure was 20 × 5 s, 1 × 10 s, 3 × 20 s, 1 ×
30 s, 1 × 40 s, 2 × 1 min, and 7 × 2 min, total 20 min. From
the dynamic PET data, metabolic images were generated
using the commercially available PMOD software (Pixel-
wise Modelling Tool, PMOD Technologies). Briefly,
Gjedde-Patlak kinetic analysis [15, 16] was applied to each
voxel in the reconstructed PET images using the time
course of radioactivity concentration in arterial blood as in-
put function (aorta-VOI in patient #1) and the time course
of radioactivity concentration in each voxel (liver tissue) as
output function. The procedure yields 3D metabolic images
of the regional hepatic blood clearance of 18F-FDGal (K,
mL blood/mL tissue/min) [10, 11].
The static PET data were reconstructed using resolution
modelling, 336 × 336 matrix, voxel size 2 × 2 × 2 mm3, 3
iterations, 21 subsets, separate prompts/randoms, and a
3.0-mm FWHM Gaussian post reconstruction filter. Stan-
dardized uptake values (SUV) of 18F-FDGal were calcu-
lated by dividing the tissue radioactivity concentration by
the injected dose and body weight.
Data analysis
An experienced radiologist (LPL) identified HCC tumours
on the diagnostic ce-CT, and volumes-of-interest (VOIs)
were defined encircling all visible tumours (tumour-VOI).
Using the fusion tool in PMOD, the reconstructed PET im-
ages were fused with the diagnostic ce-CT and the VOI was
moved in 3D to ensure the best possible match (Fig. 1).
A VOI in background liver tissue was defined in an area
without tumours and large blood vessels, approximately
1 cm from the edge of the liver (average volume was
39 mL liver tissue; range, 10–83 mL liver tissue), and used
as background-VOI. The average values (K from meta-
bolic images and SUV from static images) were obtained
in the tumour-VOI and the background-VOI to calculate
a T/B ratio. Tumours with a ratio <1 were defined as cold,
and tumours with a ratio >1 were defined as hot. Further-
more, a Tpeak/B ratio was calculated using the average
values of the five voxels with the highest values in the hot
tumours (K from metabolic images and SUV from static
images) divided by the average value in background liver
Fig. 1 Contrast-enhanced CT image (arterial phase) with VOI-definition around the hypervascular HCC tumour (a) fused with the metabolic PET
image (b), with the 1-h static image (c), and with the 2-h static image (d)
Horsager et al. EJNMMI Research  (2016) 6:56 Page 3 of 7
tissue. The images from the static whole-body PET/CT
were carefully inspected for lesions with high 18F-FDGal
accumulation outside the liver (extrahepatic disease).
Statistics
Volumes of the tumour-VOI in hot vs. cold lesions were
compared by the Mann-Whitney U test (non-normal
distribution). T/B ratios from parametric images (K) and
late static scan (SUV) were compared to T/B ratios from
the static PET scan after 1 h using a paired t test. The
paired t test was also used to compare Tpeak/B ratios
from parametric and late static PET scan against the
PET scan after 1 h. A P value <0.05 was considered to
indicate a statistically significant difference.
Results
This study included 10 patients with a total of 15 hepatic
lesions; patient characteristics are shown in Table 1.
Nine patients had cirrhosis, and the aetiology was alco-
hol in six patients and hepatitis C virus (HCV) in three
patients.
Of the 15 hepatic lesions, eight were defined as hot and
seven as cold. Twelve/fifteen tumours found on ce-CT were
identified on 18F-FDGal PET/CT. Six tumours were easier
to identify on the static images, one was easier to identify
on the metabolic image, and five tumours were identified
equally well using all three PET/CT protocols. Three of the
ce-CT-diagnosed tumours could not be identified on PET
images (tumours 2B, 9A, and 9D in Table 2). As seen in
Table 2, tumour 2B had the highest T/B ratio among the
cold tumours, i.e. closest to unity, and tumours 9A and 9D
had the lowest T/B ratios among the hot tumours, i.e. clos-
est to unity. The calculated ratios were thus in agreement
with the visual impression of these three tumours as they
differed least from the background liver tissue. One previ-
ously unknown extrahepatic metastasis in the left femoral
bone was detected in patient #6, and it was visible on PET
images acquired after 1 and 3 h (Fig. 2).
The three patients with HCV all had cold tumours,
and all hot tumours were found in patients with alcohol-
induced cirrhosis. One patient had multiple tumours in
a non-cirrhotic liver (patient #5). The 12 tumours visible
on PET had the same appearance on all three tested
methods, i.e. a hot tumour on the metabolic image was
also hot on the two static images. The three unidentified
tumours (by PET) where considered hot/cold depending
on their ratios. In tumour 9A, the ratio from the meta-
bolic image was 0.97, i.e. cold, but >1 in the two static
images, i.e. hot (Table 2). This tumour was categorized
as hot as the two static images were considered the most
reliable.
The median tumour volume, based on ce-CT, was
7 mL (range, 0.4–17 mL) for hot tumours and 39 mL
(range, 9–1550 mL) for cold tumours (U = 5, P < 0.01).
Table 2 shows the characteristics for each hepatic lesion
for each of the three PET/CT protocols. The average T/B
ratio for cold tumours was 0.62 in the metabolic images,
0.66 in the 1-h static images, and 0.68 in the 2- or 3-h
static images (P > 0.3 for all). The average T/B ratios for
hot tumours were 1.33, 1.36, and 1.34, respectively (P > 0.3
for all; Table 2). Tumours 4B, 7A, and 9A did however
have a higher or lower observed value in one protocol
compared to the two others (Table 2); 4B had a higher ra-
tio in the 2-h static image, and both 7A and 9A had a
lower value in the metabolic image compared to the two
other PET/CT protocols. However, the deviations were
not systematic since the other tumours did not follow this
pattern.
Tpeak/B ratios for the tumours are given in Table 2.
Metabolic images systematically yielded higher Tpeak/B ra-
tios than the two static images (Fig. 3) with a mean Tpeak/B
ratio of 3.12 vs. 2.33 for the 1-h static PET scan (P < 0.05).
There was no statistically significant difference between the
Table 1 Patient characteristics
Patient
ID








Time from ce-CT to PET
(days)
1 53 F 1 + + C HCV 3 46
2 71 M 2 + + A Alcohol 295,800 46
3 65 M 1 + + A Alcohol 11 9
4 62 M 2 − + C Alcohol 55 4
5 70 F 1a + − N/A − 4 13
6 69 M 1 + + B HCV 17,102 13
7 61 F 1 + + A HCV 298 15
8 67 M 1 + + B Alcohol N/A 35
9 64 M 4 − + A Alcohol 38 11
10 59 M 1 − + A Alcohol 4 25
F female, M male, HCC hepatocellular carcinoma, HCV hepatitis C virus, aFP alpha-fetoprotein, ce-CT contrast-enhanced CT, N/A not applicable
aThis patient had multiple tumours, but only one was isolated for VOI-definition on ce-CT scan
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Tpeak/B ratios from the two static protocols (P > 0.3), but
the two ratios were higher in the 2- or 3-h static protocol
than in the 1-h static protocol (tumours 4A and 4B,
Table 2).
Since the analysis was based on HCC lesions visible on
ce-CT and co-registered with PET images, we did not
observe any interobserver differences in the results (data
not shown).
Discussion
The main result from the study is that there were no sig-
nificant differences in the T/B ratio for intrahepatic
HCC lesions when comparing the three tested 18F-
FDGal PET/CT protocols, i.e. metabolic images, static
images after 1 h, and static images after 2 or 3 h after
intravenous injection of 18F-FDGal. The static PET im-
ages detected previously unknown extrahepatic disease
in one patient, which underlines the importance of per-
forming whole-body PET and not just PET of the liver.
The extrahepatic metastasis was identified equally well
on the two static image protocols.
The study was conducted in patients with known HCC
tumours because the aim was to evaluate the differences
between three 18F-FDGal PET imaging protocols and not
to test the diagnostic performance of 18F-FDGal PET vs.
conventional morphologic imaging modalities (ultrasound,
ce-CT, and MRI). The number of patients may be rela-
tively small but with a strong, paired design. With the re-
sults from the present study, a sample size of several
thousands would have been necessary to show a statistical
difference which means that for all practical purposes,
there is no difference. Based on this, we did not find it
ethical to include more patients.
Interpretation of 18F-FDGal PET/CT images is chal-
lenged by the very high uptake in normal liver tissue and
heterogeneous uptake in cirrhotic patients. To identify
HCC tumours, tracer uptake must be either significantly
higher or lower in tumour compared to background liver
tissue. The intrahepatic variation in tracer uptake is more
pronounced in the metabolic images than in the smoother
static image because of more image noise and probably be-
cause the metabolic images provide clearance values
whereas tracer in blood and non-metabolized tracer in he-
patocytes contribute to the radioactivity concentration in
the static images. This might be the reason why six intra-
hepatic HCC lesions were easier to identify on the static
images and only one was easier to identify on the meta-
bolic image in spite of the fact that statistically, the meta-
bolic images yielded higher Tpeak/B ratios than the static
images. Moreover, this analysis was only possible to con-
duct in 8/15 tumours because the remaining tumours were
classified as cold and metabolic images are also only
















2 or 3 h
1 1A (cold) 8.6 0.44 0.51 0.49 – – –
2 2A (cold) 1548 0.56 0.52 0.55 – – –
2B (cold) 39 0.86 0.89 0.90 – – –
3 3A (hot) 10 1.42 1.49 1.38 2.72 2.39 2.43
4 4A (hot) 7.8 1.61 1.56 1.46 4.94 2.56 3.13
4B (hot) 0.92 1.69 1.76 1.93 3.84 3.21 3.74
5 5A (cold) 11 n.d. 0.69 0.73 – – –
6 6A (cold) 492 0.58 0.59 0.64 – – –
7 7A (cold) 21 0.60 0.82 0.86 – – –
8 8A (hot) 17 1.05 1.12 1.14 2.60 2.06 2.13
9 9A (hot) 0.43 0.97 1.19 1.10 1.59 1.48 1.30
9B (hot) 5.0 1.29 1.26 1.24 2.74 2.06 1.98
9C (hot) 13 1.39 1.33 1.31 4.73 3.38 3.36
9D (hot) 0.58 1.19 1.18 1.16 1.80 1.47 1.32
10 10A (cold) 311 0.66 0.61 0.57 – – –
Average (cold) 0.62 0.66 0.68 – – –
Average (hot) 1.33 1.36 1.34 3.12* 2.33 2.42
T/B ratio: ratio between the average value in tumour to the average value in background liver tissue. Tpeak/B ratio: ratio between the average value of the five
hottest voxels in tumour to the average value in background liver tissue. The late static scan was performed after 2 h in patients #1–4 and after 3 h in
patients #5–10
n.d. not determined because of major respiratory artefacts
*P ≤ 0.05 when compared to Tpeak/B ratio static 1 h
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obtained from the liver whereas static images can be per-
formed as whole-body scans. In this study, a previously un-
known metastasis was identified in the left femoral bone in
patient #6 (Fig. 2). A proof-of-concept study evaluating 39
patients with HCC with a static whole-body 18F-FDGal
PET/CT found extrahepatic disease in nine patients of
which eight were novel findings [8]. A whole-body static
PET/CT is thus essential for detecting extrahepatic metas-
tases in patients with HCC.
The diagnostic ce-CT and the PET images were fused
manually (the PET images had been attenuation-corrected
by the low-dose CT) using the PMOD fusion tool. Since
the two datasets were not obtained on the same day and
the ce-CT was acquired during inspiratory breath-hold
while PET/CT was acquired during breathing, the two
image series did not fit perfectly but a close correlation
around the tumour area was prioritized. Three tumours
(2B, 9A, and 9D) were not visible on PET, and the correl-
ation between tumour-VOI and the actual tumour area on
PET might thus be poor. However, since the tumours
could not be identified on any of the three PET images,
this probably did not affect our results.
In the present study, a cold lesion was defined as a ce-
CT-defined tumour with a low tracer uptake on the 18F-
FDGal images compared to background liver tissue on
PET fused with ce-CT. However, tumour 2A had a large
cold area defining the tumour as cold, but hot tissue was
also present at the rim of the tumour. Both areas were
encircled as tumour on ce-CT, and one might argue that
this tumour was both hot and cold. Cold areas in tu-
mours might be caused by central necrosis, but the aver-
age SUV for cold tumours were approximately 14, which
indicates that even a cold tumour has a relative high up-
take of 18F-FDGal compared to other tissues. In the
Fig. 2 Arrows show a metastasis in the left femoral bone of patient #6 detected on a static 18F-FDGal PET image (visible on both static images;
here, the 1-h static image is shown). a Transaxial slice. b Coronal slice
Fig. 3 Tpeak/B ratio for all hot tumours (average of the five voxels
with the highest value in tumour divided by the average
background value). Individual tumours are connected with a line
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present study, cold tumours were statistically larger than
hot tumours, median 39 vs. 6 mL (P < 0.01). Further-
more, the hot tumours had, in general, a regular spher-
ical shape (Fig. 1), whereas the larger cold tumours were
more irregular in shape with less clearly defined borders.
The cold tumours might thus be more aggressive and
dedifferentiated, and 18F-FDGal PET/CT may provide
prognostic value. However, since large tumours are ra-
ther easy to identify on ce-CT, diagnostic improvement
must be focused on small tumours. It is likely that 18F-
FDGal PET/CT will be more useful in finding small, hot
lesions in patients with alcohol cirrhosis than in patients
with chronic HCV, but it is beyond the scope of the
present study to answer that question which should be
addressed in a large prospective study.
Conclusions
Static whole-body PET performed 1 h after injection of
100 MBq 18F-FDGal is the recommended protocol for
both intra- and extrahepatic HCC lesions since neither
metabolic nor late static whole-body PET images offered
any advantages.
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